Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology
Healthcare
$8.27 +3.05%
+$0.36 today
- Market cap
- $288.53M
- Beta
- 0.28
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.99
52W Low $9.85High $16.76
Volume 0.13M
Average 0.11M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$41.77M
FY 2025 · Annual
Net Income
-$37.92M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 59K | 73K | 75K | 0 | 0 |
| Cost of Revenue | 123K | 9K | 0 | 343K | 0 |
| Gross Profit | (64K) | 64K | 75K | (343K) | (396K) |
| Gross Margin | -108.5% | 87.7% | 100.0% | — | — |
| Research & Development | 7.02M | 11.27M | 12.77M | 15.61M | 18.33M |
| Selling, General & Admin | 6.51M | 6.65M | 6.38M | 6.99M | 23.43M |
| Operating Expenses | 13.53M | 17.92M | 19.16M | 22.49M | 41.77M |
| Depreciation & Amortization | 424K | 392K | 381K | 343K | 396K |
| EBITDA | (13.45M) | (17.78M) | (18.7M) | (22.15M) | (41.37M) |
| EBITDA Margin | -22800.0% | -24361.6% | -24933.3% | — | — |
| Operating Income | (13.6M) | (17.85M) | (19.08M) | (22.49M) | (41.77M) |
| Operating Margin | -23044.1% | -24457.5% | -25441.3% | — | — |
| Interest Income | 0 | 0 | 0 | 904K | 0 |
| Interest Expense | 6K | 32K | 33K | 0 | 0 |
| Other Income / Expenses | (286K) | (354K) | (481K) | 739K | 3.85M |
| Income Before Tax | (13.88M) | (18.21M) | (19.56M) | (21.75M) | (37.92M) |
| Pre-Tax Margin | -23528.8% | -24942.5% | -26082.7% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (13.88M) | (18.21M) | (19.56M) | (21.75M) | (37.92M) |
| Net Margin | -23528.8% | -24942.5% | -26082.7% | — | — |
| EPS (Basic) | (27.27) | (19.31) | (14.12) | (2.68) | (1.05) |
| EPS (Diluted) | (27.27) | (19.31) | (14.12) | (2.68) | (1.05) |
| 1.01M | 1.92M | 1.39M | 10.26M | 36.21M | |
| 1.01M | 1.92M | 1.39M | 10.28M | 36.21M |
BNTC Earnings Waterfall · TTM
NASDAQ:BNTC · Revenue to Net Income
Key Ratios
EPS$-1.11
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-11.7
P/S Ratio0.0
Analysis
$0 of revenue converted into -$48.9M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.11, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 13, 2026 | |
| 8-K | Current report | Oct 28, 2026 | |
| DEFA14A | DEFA14A filing | Oct 20, 2026 | |
| DEF 14A | DEF 14A filing | Oct 20, 2026 |
How much revenue does BNTC generate?
Benitec Biopharma Inc. (BNTC) reported $0.00 of revenue in fiscal 2025.
Is BNTC profitable?
Benitec Biopharma Inc. (BNTC) reported -$37.92M of net income.
Continue the stock analysis
Jump to another research area for this company.